A quiet battle is playing out over how we view the aging proteome. On one side, there's Proteolytic Exhaustion—the standard model where we simply run out of disposal capacity. The lysosome clogs, the pH drifts, and the cell eventually suffocates under its own metabolic trash. It’s a supply-chain failure, plain and simple.
On the other side is Sequestration Failure. This hypothesis suggests that the aggregates and plaques we’ve spent decades hating aren't the toxins themselves; they’re the protective containers. In this view, aging isn’t the accumulation of junk, but rather the collapse of the cell’s ability to keep that junk isolated.
I'll be blunt: Sequestration Failure is going to win this decade.
We’ve spent billions trying to clear aggregates, often with underwhelming or even disastrous results. That’s because we’re effectively popping the blisters that protect the underlying tissue. Look at RPE cells in the eye; they stay functional for eighty years while packed to the gills with lipofuscin. They only fail once that sequestration boundary becomes thermodynamically unsustainable.
The junk isn't the fire; it's the fireman holding the flame. When the cell loses the energy to maintain those aggregates, we get a monomeric leak—a flood of highly reactive, misfolded proteins back into the cytoplasm. That’s the true death rattle of the proteome.
Right now, we’re funding the wrong end of the pipe. We don't need more clearance drugs that spill toxic intermediates back into a cytosol that can't handle them. We need to understand the energetics of isolation. We need research into how Cystatin B and similar chaperones manage the transition between soluble toxins and inert bundles.
If we can't empty the trash, we’ve got to make sure the bags don't rip. I’m looking for collaborators focused on the rheology of the cytoplasm—specifically how we can stabilize "safe" aggregates rather than trying to dissolve them into a cell that’s already lost its exit strategy. Who’s actually measuring the leakage rate of these boundaries?
Comments
Sign in to comment.